CBTG - Cabot Growth ETF
| Assets | $39.61M |
| NAV | $29.34 |
| Expense Ratio | 0.77% |
| PE Ratio | n/a |
| Beta (5Y) | 1.64 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| 1-Year Return | - |
| Trading Day | April 16 |
| Last Price | $29.34 |
| Previous Close | $29.69 |
| Change ($) | -0.35 |
| Change (%) | -1.18% |
| Day's Open | 29.89 |
| Day's Range | 29.30 - 29.89 |
| Day's Volume | 11,174 |
| 52-Week Range | 24.64 - 33.16 |
Fund Description
The investment seeks capital appreciation. The fund may invest in common stock of U.S. large-, mid-, and small-capitalization companies and ETFs. It also may invest to a lesser extent in American Depositary Receipts (ADRs) representing foreign company stock. Under normal circumstances, 70-80% of the fund's net assets, plus borrowings for investment purposes, will be invested in equity securities. The fund is non-diversified.
| Asset Class Equity | Inception Date Dec 30, 2020 |
| Exchange BATS | Ticker Symbol CBTG |
Top 10 Holdings
70.17% of assets| Name | Symbol | Weight |
|---|---|---|
| Akoustis Technologies | AKTS | 16.69% |
| The Trade Desk | TTD | 12.95% |
| Chesapeake Energy | CHK | 8.52% |
| Bombardier Inc | BBD.B.TO | 5.65% |
| Rolls-Royce Holdings PLC ADR | RYCEY | 5.63% |
| VYNE Therapeutics | VYNE | 4.79% |
| Mimecast | MIME | 4.47% |
| Inseego | INSG | 4.14% |
| Kura Oncology | KURA | 4.06% |
| PubMatic | PUBM | 3.27% |
Growth stocks remain a compelling market segment and there opportunities abound for active managers to deliver alpha in this arena. The newly minted Cabot Growth ETF (CBOE:CBTG) brings a fresh approach ...
SOUTHFIELD, Mich., Feb. 1, 2021 /PRNewswire/ -- Cabot ETF Partners is proud to announce the new Cabot Growth ETF (Symbol: CBTG). This Fund, powered by Cabot ETF Partners, began trading on the CBOE on De...
